Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TSC-201-B0702 + TSC-202-A0201
- Development stage
- Unknown
- Lead developer
- TCRx Therapeutics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TSC-201-B0702 + TSC-202-A0201 is a combination of two autologous, engineered TCR-T cell therapies developed by TScan Therapeutics for the treatment of solid tumors. Each component targets a distinct cancer-testis antigen presented by specific HLA molecules on tumor cells. TSC-201-B0702 targets MAGE-C2 (MAGE family member C2) in the context of HLA-B*07:02, while TSC-202-A0201 targets MAGEA4 (Melanoma-associated antigen 4) in the context of HLA-A*02:01. Both are designed to recognize and eliminate tumor cells expressing these antigens with high specificity and potency, showing anti-tumor activity in preclinical models and resistance to immunosuppressive signals such as those mediated by transforming growth factor beta (TGFβ). The therapies are being evaluated in Phase 1 clinical trials for multiple HPV-related cancers and other solid tumors including melanoma, non-small cell lung cancer, head and neck cancers, anal carcinoma, cervical cancer, sarcoma, uterine cervical cancer, and others[2][5][7].
- Other names
- TSC-201(HLA-B*07:02)TSC-202TSC202TSC 202
02
Targets
MAGE-A4 peptide-HLA-A*02:01 complexpMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on TSC-201-B0702 + TSC-202-A0201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TSC-201-B0702 + TSC-202-A0201.